The primary and essential use of Larin Fe 1/20 is for pregnancy prevention, and it may be part of symptomatic management, supporting women who choose this oral regimen. Beyond this foundational function, the medication is applied across therapeutic domains where additional symptomatic support is needed.

The medication is commonly used to address symptoms related to systemic imbalance, including heavy menstrual bleeding, severe uterine cramping (dysmenorrhea), and moderate acne vulgaris. This application plays a role in managing symptom clusters that may become intense or disruptive. The treatment supports general well-being during symptomatic phases by contributing to a more manageable menstrual experience.

This approach assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.

Focus: Menstrual Discomfort Larin Fe 1/20 is commonly used to help ease the overall symptom burden of menstruation, which may assist with maintaining functional stability and contributes to improved comfort.

Regulatory References

1. Oral Contraceptive Pills Overview from the National Institutes of Health (NIH)

Eligibility for Larin Fe 1/20

Larin Fe 1/20 is officially indicated for use in postmenarchal females of reproductive potential for pregnancy prevention, and for the treatment of moderate acne vulgaris in eligible women. Regulatory authorities strictly define the population allowed to use this medication, largely based on screening for risks related to serious cardiovascular events.

Absolute Contraindications (Must Not Use)

This medicine is contraindicated and must not be used by specific population groups due to significantly increased risk, as defined in regulatory labeling:

• Age and Smoking: Women aged 35 years or older who smoke cigarettes.
• Thrombotic History: Individuals with a current or past diagnosis of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Disease, or Coronary Artery Disease.
• Malignancy: Current or history of breast cancer or other known/suspected estrogen-dependent neoplasia.
• Hepatic Status: Active liver disease or liver tumors.
• Cardiovascular/Metabolic: Uncontrolled hypertension, diabetes mellitus with vascular disease, or migraine headaches with aura.
• Pregnancy: Known or suspected pregnancy.

Restricted and Age-Based Use

Classification	Regulatory Status
Pediatric Use	Limited to postmenarchal patients.
Geriatric Use	Use not established; no information is available.
Lactation	Use is not recommended, as it may reduce milk production.
Surgery/Immobilization	Must be discontinued at least 4 weeks before and 2 weeks after major surgery or prolonged immobilization.

The official regulatory profile for Larin Fe 1/20 (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate) documents several interactions that alter drug exposure and impose specific restrictions.

---

Formally Contraindicated Combinations

Co-administration with combination drug regimens for Hepatitis C Virus (HCV) containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, is formally contraindicated due to the risk of significant liver enzyme (ALT) elevation.

In a population-specific restriction, the use of combined oral contraceptives is also contraindicated in females over 35 years of age who smoke due to the documented substantial increase in the risk of serious cardiovascular events.

---

Exposure-Altering Interactions

Certain medicinal products classified as enzyme inducers (e.g., Rifampin, Anticonvulsants such as Phenytoin or Carbamazepine, and the herbal product St. John's Wort) may accelerate the metabolism and clearance of the hormonal components, potentially leading to reduced contraceptive effectiveness.

Conversely, the plasma concentrations of certain co-administered drugs, such as Cyclosporine and Prednisolone, may be increased due to the hormonal components altering their clearance.

---

Non-Hormonal Component Restrictions

The non-hormonal Ferrous Fumarate component can decrease the absorption of other co-administered medicines, including Thyroid Medications (e.g., Levothyroxine) and Bisphosphonates. This interference necessitates mandatory timing separation for administration of the iron tablets from these medicines, as well as from foods, dairy products, coffee, or tea.

How Larin Fe 1/20 Works

Larin Fe 1/20 works through the combined pharmacodynamic actions of its synthetic estrogen and progestin components to modulate the hypothalamic-pituitary-ovarian ( HPO) axis and peripheral tissues.

Central Modulation of the HPO Axis

The primary mechanistic action involves providing continuous negative feedback to the hypothalamus and pituitary gland. This signaling suppression blocks the pulsatile release of Gonadotropin-Releasing Hormone ( GnRH), which consequently inhibits the pituitary secretion of Follicle-Stimulating Hormone ( FSH) and Luteinizing Hormone ( LH). This cascade alters the hormonal signaling necessary for follicular maturation and the LH surge, which is required for the development and release of an oocyte.

Local and Systemic Effects

The progestin component induces local effects on the reproductive tract. This includes altering cervical mucus viscosity, which impedes sperm motility, and promoting structural changes in the endometrium that affect uterine lining receptivity. Systemically, the estrogen component modulates hepatic protein synthesis, leading to an increase in Sex Hormone-Binding Globulin ( SHBG). This cascade reduces the amount of biologically active, unbound androgens in circulation, contributing to the reduction of free androgen availability to peripheral tissues.

Larin Fe 1/20 is administered orally and is structured as a continuous 28-day regimen designed for long-term use. The complete cycle consists of 21 active tablets (containing 1 mg Norethindrone Acetate and 20 mcg Ethinyl Estradiol) followed by seven brown, non-hormonal tablets (containing 75 mg Ferrous Fumarate). These inactive tablets are included solely to support the daily dosing routine without contributing to the hormonal effect.

The standardized approach involves taking one tablet daily at the same time each day to maintain a consistent 24-hour dosing interval. The medication may be taken with a meal or at bedtime to aid compliance. The tablets are taken in the sequential order indicated on the blister pack, ensuring the transition from the active hormonal phase to the non-hormonal phase.

When initiating the medication, two patterns are available: the Day-1 Start or the Sunday-Start regimen. If the Sunday-Start method is chosen, an additional, non-hormonal back-up contraceptive method is used for the first seven days of the initial cycle. In the event that unscheduled spotting or breakthrough bleeding occurs while taking the active tablets, the medication is continued without interruption. Dosing for postpubertal adolescents follows the same principles as the adult regimen, but the drug is not indicated for use before menarche.

Research evidence / Overview of Studies for Larin Fe 1/20

Evidence for Use in Pregnancy Prevention

Research for this medication's contraceptive use has been conducted primarily through clinical trials and follow-up data collection, with studies designed to measure pregnancy rates. These studies focused on women of reproductive age who were observed in research contexts involving oral contraceptives. The primary variable of interest in the research was measured using standardized metrics, such as the Pearl Index (PI) and life-table pregnancy rates, which are research tools used to track failure rates over a defined period of study. The available research provides context for the range of pregnancy rates observed over approximately one year of study duration. The consistency of findings across these studies is documented in the evidence base for this indication.

Evidence for Use in Moderate Acne Vulgaris

Research examining this formulation for conditions characterized by inflammatory states, such as moderate acne vulgaris, comes from dedicated studies. These were often short-term Randomized, Double-Blind, Placebo-Controlled Trials (RCTs), where a treatment was compared against an inactive substance (placebo) to explore changes in skin condition. The research examined specific outcomes related to skin condition, such as counts of acne lesions and Investigator’s Global Assessments. Study populations were limited to females who also sought an oral contraceptive method. Long-term outcomes related to skin condition beyond the initial six months are less fully established by these specific trials.

Evidence for Symptomatic Management (Heavy Bleeding and Cramping)

Research exploring outcomes related to physical discomfort, such as heavy menstrual bleeding (menorrhagia) and severe uterine cramping (dysmenorrhea), generally relies on evidence gathered from the broader Combined Oral Contraceptive (COC) class. Findings indicate that combined oral contraceptives were associated with observed patterns related to symptom measurements. The evidence base for these symptomatic applications is derived primarily from the general class of combined oral contraceptives, and controlled trials specific to this exact low-dose formulation may be limited.

What is Still Uncertain about Larin Fe 1/20 Research

A key limitation described in the research is the lack of specific efficacy data for women with a high Body Mass Index (BMI > 35 kg/m²). The results apply only to the populations studied. Comparative evidence is lacking, and research provides context but not individual predictions for this specific population. The long-term observations extending many years are also not fully established by the primary registration trials, with data on extended use generally contributing to the broader evidence landscape through ongoing post-marketing surveillance.

Key Studies & References JUNEL Fe 1/20 (Norethindrone Acetate and Ethinyl Estradiol Tablets) Full Prescribing Information

Common questions about Larin Fe 1/20 (FAQ)

---

Q: Is Larin Fe 1/20 a generic version of something else?

Larin Fe 1/20 is a generic medication. Regulatory documents indicate it is a combination product containing the active hormones norethindrone acetate and ethinyl estradiol, along with non-hormonal ferrous fumarate (iron) tablets.

---

Q: Is Larin Fe 1/20 considered a 'low dose' birth control?

Official product information states the active tablet contains 20 mu g of ethinyl estradiol. This amount is generally considered a low-dose formulation within the category of combined oral contraceptives.

---

Q: Do you always get a period when taking Larin Fe 1/20?

No. Official product information notes that bleeding irregularities are possible when using the medication. This includes the possibility of a complete absence of the expected withdrawal bleed, a condition known as amenorrhea.

---

Q: Is there a maximum age limit for using Larin Fe 1/20?

The official Boxed Warning for combined oral contraceptives restricts use in women over 35 years of age who smoke cigarettes. This restriction is due to a significantly increased risk of serious cardiovascular events in this population.

---

Q: Why is it recommended to take Larin Fe 1/20 at the same time every day?

The prescribing information indicates taking the drug at the same time every day helps maintain consistent hormonal levels necessary to support maximum contraceptive effectiveness.

---

Q: What is the significance of the '1/20' in the name Larin Fe 1/20?

The numbers in the name are a shorthand for the dosage of the two active components. Official documentation confirms it corresponds to 1 mg of norethindrone acetate and 20 mu g of ethinyl estradiol.

---

Q: What is the difference between Larin Fe 1/20 and Larin 24 Fe?

The key difference is the tablet structure within the 28-day regimen. Larin Fe 1/20 has 21 active (hormonal) tablets and 7 inactive tablets. In contrast, Larin 24 Fe regimens are structured with 24 active tablets and 4 inactive tablets.

---

Q: What if I forget to take Larin Fe 1/20 for one day?

The patient instructions provide guidance for dealing with late or missed pills. This often requires specific action and may involve using a non-hormonal backup contraceptive method depending on how many pills were missed.

---

Q: Can Larin Fe 1/20 interact with common over-the-counter pain relievers?

Official regulatory documents list specific drug interactions for combined oral contraceptives. This list includes common over-the-counter pain relievers, such as Ibuprofen.

---

Q: Can antibiotics reduce the effectiveness of Larin Fe 1/20?

Yes, the Drug Interactions section of the official label states that some antibiotics may reduce the effectiveness of combined oral contraceptives. This interaction could potentially lead to contraceptive failure and breakthrough bleeding.

---

Q: What happens when you stop taking Larin Fe 1/20?

Stopping the use of combined oral contraceptives is not associated with long-term impairment of future fertility. However, a delay in the return of normal menstrual cycles may be observed.

---

Q: What should be done if vomiting occurs after taking Larin Fe 1/20?

The prescribing information includes specific advice for dealing with severe gastrointestinal disturbances, such as vomiting or diarrhea. This advice is provided for cases where the disturbance occurs shortly after taking an active (hormonal) tablet.

---

Q: Is a delay in returning to normal menstrual cycles expected after stopping Larin Fe 1/20?

A delay in the return of normal menstrual cycles is a possibility after stopping combined oral contraceptives. This temporary condition is sometimes referred to as post-pill amenorrhea.

---

Q: Can Larin Fe 1/20 be taken if I am lactose intolerant?

The official product description indicates that the active tablets contain lactose as an inactive ingredient. This is important information for individuals with known lactose intolerance.

---

Q: Do official prescribing documents mention anything about Larin Fe 1/20 and hair loss?

Yes, the comprehensive list of reported adverse reactions for combined oral contraceptives includes effects such as alopecia (hair loss).

---

Q: What kind of follow-up care is typically associated with starting Larin Fe 1/20?

Official guidance considers it good medical practice for a person to have annual physical examinations while using oral contraceptives. This monitoring includes checks on blood pressure, breasts, pelvic organs, and relevant laboratory tests.

---

Q: Does Larin Fe 1/20 affect future fertility?

Official product information indicates that the use of combined oral contraceptives is not associated with long-term impairment of future fertility.

---

Q: Does Larin Fe 1/20 have a long half-life?

The Clinical Pharmacology section lists the elimination half-life for the hormonal components. Norethindrone has a half-life of approximately 8.6 hours, and ethinyl estradiol is approximately 17.1 hours.

---

Q: Can Larin Fe 1/20 affect cholesterol levels?

Official Warnings and Precautions note that combined oral contraceptives may cause changes in carbohydrate and lipid metabolism. This includes the potential for some progestogens to elevate LDL levels (a type of cholesterol).

---

Q: Is there a black box warning associated with Larin Fe 1/20, according to the FDA?

Yes, the FDA label for combined oral contraceptives contains a prominent Boxed Warning. This warning specifically highlights the risk associated with Cigarette Smoking and Serious Cardiovascular Events.

Larin Fe 1/20 must be stored under specific conditions defined by regulatory documents to ensure product stability and safety.

Official Storage Requirements

The medication must be maintained at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from light. As a mandatory safety measure, Larin Fe 1/20 must be kept out of the reach of children, primarily due to the risk of accidental iron overdose associated with the ferrous fumarate component.

Official Disposal Instructions

To dispose of unused or expired Larin Fe 1/20, consumers should first check for specific disposal instructions on the label. The official preferred method is to utilize a drug take-back program. If a take-back program is unavailable, the product may be discarded in the household trash after being mixed with an undesirable substance, such as coffee grounds or kitty litter, and secured in a sealed container.